Cingulate Inc. (NASDAQ: CING) reported a net loss of $9.3 million for Q1 2026, compared to a loss of $3.9 million in the same period last year.
The company's cash and cash equivalents increased to $25.9 million, up $14.9 million from year-end 2025. This was driven by a $12.0 million private placement in February 2026.
General and administrative expenses rose to $5.7 million, attributed to building commercial infrastructure for its ADHD treatment candidate, CTx-1301.
R&D expenses slightly decreased to $2.2 million. Cingulate is working with the FDA to address manufacturing and quality control issues for CTx-1301.
The company believes its current capital is sufficient to fund operations into 2027.
